Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9291 rifampicin drug-drug interaction study in EGFR-mutant NSCLC
NL-OMON44697Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Effect of rifampicin on AZD9291 steady-state exposure. Started Jan 2015; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON44697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44697.